Page last updated: 2024-11-04

vorinostat and Candidiasis

vorinostat has been researched along with Candidiasis in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Candidiasis: Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Han, G2
Liu, N2
Li, C1
Tu, J2
Li, Z2
Sheng, C2

Other Studies

2 other studies available for vorinostat and Candidiasis

ArticleYear
Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
    Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10

    Topics: 14-alpha Demethylase Inhibitors; Animals; Azoles; Candida albicans; Candidiasis; Cytochrome P450 Fam

2020
Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
    Journal of medicinal chemistry, 2021, 01-28, Volume: 64, Issue:2

    Topics: Animals; Azoles; Biofilms; Candida albicans; Candidiasis; Carbolines; Drug Resistance, Fungal; Drug

2021